Abstract
BackgroundWhile immune-based therapies induce durable remissions in subsets of patients across a wide range of malignancies, efficacy in metastatic castrate-resistant prostate cancer (mCRPC) is limited.1–3 One hypothesis for immunotherapy failure...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
